Treatment-Resistant Anxiety: Reassessment, Sequencing, and Collaborative Care

Narrative Review. This page provides the verified citation, abstract, and full-text PDF for the journal article.

Clinical boundary: Persistent anxiety requires reassessment before escalation. Medication selection, combinations, tapering, interactions, and monitoring need a qualified prescriber; abrupt benzodiazepine withdrawal may be dangerous.

Publication Details

Author: Christian Jonathan Haverkampf
Journal: The Journal of Psychiatry Psychotherapy and Communication
Publication date: 2023-06-30
Volume, issue, pages: 12(2), 31–40
Article type: Narrative Review

Recommended citation: Haverkampf, C. J. (2023). Treatment-Resistant Anxiety: Reassessment, Sequencing, and Collaborative Care. The Journal of Psychiatry Psychotherapy and Communication, 12(2), 31–40.

Abstract

Persistent anxiety after treatment is common, but “treatment-resistant anxiety” does not describe a uniform disorder or outcome. It may reflect inadequate treatment, intolerance, nonresponse, partial response, relapse, persistent avoidance, or functional nonrecovery across generalized anxiety, panic, agoraphobia, and social anxiety disorders. This narrative review synthesizes evidence and guidance available through 30 May 2023. Before escalation, clinicians should conduct a resistance audit that confirms diagnosis, risk, comorbidity, medical and substance-related differentials, context, treatment adequacy, implementation, tolerability, psychotherapy fidelity, safety behaviors, and measured outcomes. First-line care remains adequately delivered disorder-specific cognitive behavioral therapy, including exposure where indicated, and/or an evidence-supported antidepressant selected through shared decision making. After limited response, clinicians may optimize an incomplete but beneficial treatment, add missing active procedures, switch after verified nonresponse or intolerance, combine modalities, or seek specialist review. Pharmacologic augmentation has a narrower evidence base and requires a defined target, monitoring plan, review date, and stopping rule. Long-term benzodiazepine use is generally not preferred, and abrupt withdrawal may be dangerous. Communication-focused formulation is presented as an author-developed adjunct rather than a substitute for established care. The principal conclusion is that resistance is a provisional classification of a treatment episode, not a fixed patient attribute.

Keywords

treatment-resistant anxiety; generalized anxiety disorder; panic disorder; social anxiety disorder; cognitive behavioral therapy; pharmacotherapy; reassessment

Full Text

Open the full-text PDF

The PDF is searchable and preserves the journal layout and pagination used in the citation.

Related Information

Health Information and Safety

This journal article is educational and research-oriented. It is not a personal diagnosis, treatment plan, medication instruction, crisis service, or substitute for assessment by a suitably qualified clinician who knows the person’s circumstances.

Do not start, stop, or change medication or another treatment solely because of information on this page. New, severe, persistent, or worsening symptoms, or uncertainty about risk, require individual professional assessment.

If there is immediate danger or a risk of harm, contact local emergency services or urgent support. In Ireland, see:

Website copy first made available on 26 August 2026. The journal citation retains the article’s issue date.